Alflutinib (AST-2818; Furmonertinib; ASK120067) is an irreversible EGFR inhibitor that has been approved in China on March 3, 2021 for treatment of EGFR T790M+ NSCLC. A phase 3 trial FLAG comparing alflutinib with gefitinib in 1L treatment of patients with EGFR+ NSCLC is ongoing (NCT03787992)

纯度：≥98%

CAS：1869057-83-9